1. Home
  2. CERE

CERE

Cerevel Therapeutics Holdings Inc.

Logo Cerevel Therapeutics Holdings Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Founded: 2018 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 7.7B IPO Year: N/A
Target Price: $40.36 AVG Volume (30 days): 1.5M
Analyst Decision: Hold Number of Analysts: 11
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.67 EPS Growth: N/A
52 Week Low/High: $19.59 - $43.59 Next Earning Date: 05-01-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: